Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic
- PMID: 28097342
- PMCID: PMC5507610
- DOI: 10.1001/jama.2016.18631
Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic
Conflict of interest statement
Comment on
-
Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.JAMA. 2017 Jan 10;317(2):146-155. doi: 10.1001/jama.2016.19456. JAMA. 2017. PMID: 28097355 Clinical Trial.
-
Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.JAMA. 2017 Jan 10;317(2):156-164. doi: 10.1001/jama.2016.19468. JAMA. 2017. PMID: 28097356 Clinical Trial.
References
-
- Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–2218. - PubMed
-
- Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol. 2014;10(5):268–278. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical